World's largest producer of heparin active pharmaceutical ingredient, sourced from pig intestines and sold globally as a blood-thinner API.
World's largest producer of heparin active pharmaceutical ingredient, sourced from pig intestines and sold globally as a blood-thinner API.
Sells heparin API mainly to other drugmakers, which turn it into enoxaparin and other blood thinners, and also sells its own finished enoxaparin injections, which pay more per unit. Its US arm is Scientific Protein Laboratories, so raw-material and plant capacity sit in several countries.
In one line: The world's dominant heparin API supplier.
Moat: narrow (scale, regulatory licence, installed base). Largest global heparin API capacity and FDA/EU-approved supply chain, hard to replicate at scale.
Headquarters: Shenzhen, China · Founded: 1998 · Employees: 2,150
Size Shenzhen Hepalink Pharmaceutical (002399.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.80B, the 1277th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.06 on 18 Nov 2026.
Performance Over six months the shares fell 12.4%, against -7.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 6.0% over the last twelve months (peer median +6.7%); the operating margin is 7.7% (peer median 10.0%).
Valuation It trades at 25.8× forward earnings against a peer median of 19.1× (4th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.4 points below its cost of capital (7.2% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.08B | CN¥5.46B | CN¥5.28B | CN¥5.44B | CN¥7.16B |
| Revenue growth | — | +3% | -3% | -24% | — |
| Gross profit | CN¥1.94B | CN¥1.62B | CN¥1.66B | CN¥1.70B | CN¥2.24B |
| EBITDA | n/a | CN¥886M | CN¥1.05B | CN¥125M | CN¥1.30B |
| Net income | CN¥190M | CN¥349M | CN¥647M | -CN¥783M | CN¥727M |
| Free cash flow | CN¥1.96B | CN¥1.61B | CN¥2.28B | CN¥26.5M | -CN¥844M |
| Capital expenditure | CN¥106M | CN¥121M | CN¥203M | CN¥445M | CN¥222M |
| Total debt | CN¥3.10B | CN¥2.97B | CN¥3.54B | CN¥5.56B | CN¥6.46B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002399.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.6% | +0.1% | 8th lowest of 21 |
| 6-month return | -12.4% | -7.3% | 10th lowest of 21 |
| Distance from 52-week high | -28.6% | -33.7% | 9th highest of 21 |
| Revenue growth (TTM) | -6.0% | +6.7% | 6th lowest of 21 |
| Operating margin | 7.7% | 10.0% | 10th lowest of 21 |
| Forward P/E | 25.8× | 19.1× | 4th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | -0.7% | 6.7% | 6th least demanding of 15 |
| Growth delivered (Del g) | +0.5% | +8.1% | lowest of 15 |
| Hurdle (Req g minus delivered) | -1.2 pp | -9.0 pp | 6th most demanding of 15 |
| ROIC minus cost of capital | -2.4 pp | +2.4 pp | 10th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |